Single Dose of REGEN-COV Provides Long-Term Protection

Regeneron Pharmaceuticals, Inc. announced on November 8, 2021, a single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8).

And during the 8-month assessment period, there were (0) hospitalizations for COVID-19 in the REGEN-COV group.

The company stated in a press release the 'fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without any artificial mutations or sequences.'

"In this phase 3 trial, a single dose of REGEN-COV provided long-term protection against COVID-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure," commented George D. Yancopoulos, M.D., Ph.D., President, and Chief Scientific Officer at Regeneron.

"These data add to the increasing body of evidence supporting the use of REGEN-COV to prevent COVID-19 in uninfected individuals, which may be especially useful for the many immunocompromised people who do not respond adequately to vaccines and remain 'prisoners of the pandemic."

"With infections still occurring despite widespread vaccination, the immunocompromised face an ongoing risk of encountering the virus during their daily lives."

"We intend to rapidly share these additional data with regulatory authorities to help those in most need of protection from COVID-19."

REGEN-COV is currently authorized in the U.S. by the FDA to treat people at high risk of serious consequences from COVID-19 infection who are either already infected (non-hospitalized) or in specific post-exposure prophylaxis settings.